WilmerHale Represents Karyopharm in Agreement with Biogen to Acquire KPT-350

WilmerHale Represents Karyopharm in Agreement with Biogen to Acquire KPT-350

Firm News

On January 25, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its entry into an agreement for Biogen to acquire Karyopharm's investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative conditions. KPT-350 is a novel therapeutic candidate that works by inhibiting XPO1, resulting in reductions in inflammation and neurotoxicity, as well as increasing neuroprotective responses.

The WilmerHale team representing Karyopharm in this deal included Steve Singer and Andrew Bonnes.

The full press release can be found at www.karyopharm.com.  

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.